Helsinn Group announces oral presentation of data at AACR-NCI-EORTC relating to a potent and highly selective investigational RET inhibitor
07 oct. 2021 09h00 HE
|
Helsinn Healthcare S.A.
Helsinn Group announces oral presentation of data at AACR-NCI-EORTC relating to a potent and highly selective investigational RET inhibitor Lugano, Switzerland, 7 October 2021 – Helsinn Group, a...
Helsinn Group and BridgeBio Pharma’s Affiliate QED Therapeutics Announce Health Canada Conditional Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma
29 sept. 2021 07h30 HE
|
Helsinn Healthcare S.A.
Helsinn Group and BridgeBio Pharma’s Affiliate QED Therapeutics Announce Health Canada Conditional Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma - Health Canada Issues...
Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care, supported by Helsinn, awarded to Patrick Johnson, MD
24 juin 2021 08h30 HE
|
Helsinn Healthcare S.A.
Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care, supported by Helsinn, awarded to Patrick Johnson, MD Lugano, Switzerland, June 24, 2021 – Helsinn, a Swiss Biopharmaceutical...
Helsinn appoints Mary Lynne Hedley to Board of Directors
29 avr. 2021 03h00 HE
|
Helsinn Healthcare S.A.
Lugano, Switzerland, April 29, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to announce the appointment of Dr. Mary Lynne...
Helsinn appoints Mary Lynne Hedley to Board of Directors
29 avr. 2021 03h00 HE
|
Helsinn Healthcare S.A.
Lugano, Switzerland, April 29, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to announce the appointment of Dr. Mary Lynne...
Helsinn Announces the Launch of Adlumiz® (anamorelin) for the Treatment of Cancer Cachexia in Japan
21 avr. 2021 02h30 HE
|
Helsinn Healthcare S.A.
Helsinn Announces the Launch of Adlumiz® (anamorelin) for the Treatment of Cancer Cachexia in Japan Lugano, Switzerland, April 21, 2021 – Helsinn, a Swiss pharmaceutical group focused on building...
Helsinn announces poster presentation at Academy of Managed Care Pharmacy (AMCP) 2021 Virtual Meeting evaluating healthcare resource utilization in CINV
13 avr. 2021 08h00 HE
|
Helsinn Healthcare S.A.
Helsinn announces poster presentation at Academy of Managed Care Pharmacy (AMCP) 2021 Virtual Meeting evaluating healthcare resource utilization in CINV Lugano, Switzerland, April 13, 2021 – Helsinn,...
BridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn Group Announce Strategic Collaboration to Co-Develop and Commercialize Infigratinib in Oncology
31 mars 2021 07h30 HE
|
Helsinn Healthcare S.A.
BridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn Group Announce Strategic Collaboration to Co-Develop and Commercialize Infigratinib in Oncology BridgeBio, through its Affiliate QED...
Helsinn publishes PROVe MF-CTCL study providing new data for mechlorethamine gel use in a real-world setting
18 mars 2021 08h30 HE
|
Helsinn Healthcare S.A.
Helsinn publishes PROVe MF-CTCL study providing new data for mechlorethamine gel use in a real-world setting Lugano, Switzerland, March 18, 2021 – Helsinn, a Swiss pharmaceutical group focused on...
Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy and safety
18 févr. 2021 08h00 HE
|
Helsinn Healthcare S.A.
Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy and safety Lugano, Switzerland, February 18, 2021 – Helsinn, a Swiss pharmaceutical group focused on...